Beckley Psytech

Beckley Psytech operates as a psychedelic medicine company. The company is involved in exploring the therapeutic potential of psychedelic substances, such as psilocybin and other compounds, for mental health treatment. The company envisions the integration of clinically validated psychedelic medicines into contemporary medical practices to assist individuals coping with depression and other significantly debilitating neuropsychiatric conditions characterized by a substantial unmet need.

Beckley Psytech headquartered in Europe, operates in the Biotechnology, Health Care, Medical sector. The company focuses on Biotechnology and has secured $13.8B in funding across 84 round(s). With a team of 11-50 employees, Beckley Psytech is actively contributing to advancements in Biotechnology. Their latest funding round, Secondary Market - Beckley Psytech, raised $10.0M. Discover more about their projects, partnerships, and impact on our platform.